To ask the Secretary of State for Health, with reference to page 21 of his Department's Pharmaceutical Price Regulation Scheme, published in December 2013, when he plans to publish information on the comparative use of medicines in the NHS referred to in that document; by which channels he plans that information to be published; what plans he has to communicate that information proactively through the NHS; whether he intends to communicate that information to patients; and if he will make a statement.
To ask the Secretary of State for Health, with reference to page 21 of his Department's Pharmaceutical Price Regulation Scheme, published in December 2013, when he plans to refresh the annual indicators arising from the Pharmaceutical Industry Competitiveness Taskforce referred to in that document; if he will make it his policy to include (a) medicines expenditure per head of population, (b) market sales as a percentage of GDP and (c) average pricing and reimbursement delays in the set of those indicators; and if he will make a statement.
The Life Science Competitiveness Indicators were published for the first time in March 2015 and are available to all. The publication can be found here:
The Competitiveness Indicators were the product of extensive collaboration with colleagues from across the life science sector, including from industry. In developing the Indicators, issues such as the availability and reliability of data, the potential for international comparisons and relevance to United Kingdom competitiveness in life sciences were considered in establishing which measures to include.
We plan to publish the 2016 Life Science Competitiveness Indicators in March 2016. Our intention is to maintain as much consistency in content as possible, in order to facilitate analysis of progress over time, which can in turn inform policy development.